twist is a potential oncogene that inhibits apoptosis

  1. Roberta Maestro,
  2. Angelo P. Dei Tos,
  3. Yasuo Hamamori,
  4. Svetlana Krasnokutsky,
  5. Vittorio Sartorelli,
  6. Larry Kedes,
  7. Claudio Doglioni,
  8. David H. Beach, and
  9. Gregory J. Hannon
  1. Experimental Oncology 1, Centro di Riferimento Oncologico, 33081 Aviano, Italy; Cold Spring Harbor Laboratory, Cold Spring Harbor, New York 11724 USA; Department of Histopathology, Treviso City Hospital, Treviso, Italy; Institute for Genetic Medicine, University of Southern California School of Medicine, Los Angeles, California 90033 USA; Department of Histopathology, Belluno City Hospital, Belluno, Italy; Institute of Child Health, London WC1N 1EH, UK

Abstract

Oncogene activation increases susceptibility to apoptosis. Thus, tumorigenesis must depend, in part, on compensating mutations that protect from programmed cell death. A functional screen for cDNAs that could counteract the proapoptotic effects of the myc oncogene identified two related bHLH family members, Twist and Dermo1. Both of these proteins inhibited oncogene- and p53-dependent cell death. Twist expression bypassed p53-induced growth arrest. These effects correlated with an ability of Twist to interfere with activation of a p53-dependent reporter and to impair induction ofp53 target genes in response to DNA damage. An underlying explanation for this observation may be provided by the ability of Twist to reduce expression of the ARF tumor suppressor. Thus, Twist may affect p53 indirectly through modulation of the ARF/MDM2/p53 pathway. Consistent with a role as a potential oncoprotein, Twist expression promoted colony formation of E1A/ras-transformed mouse embryo fibroblasts (MEFs) in soft agar. Furthermore, Twist was inappropriately expressed in 50% of rhabdomyosarcomas, a tumor that arises from skeletal muscle precursors that fail to differentiate. Twist is known to block myogenic differentiation. Thus, Twist may play multiple roles in the formation of rhabdomyosarcomas, halting terminal differentiation, inhibiting apoptosis, and interfering with thep53 tumor-suppressor pathway.

Keywords

Footnotes

  • Corresponding author.

  • E-MAIL hannon{at}cshl.org; FAX (516) 367-8874.

    • Received March 19, 1999.
    • Accepted July 7, 1999.
| Table of Contents

Life Science Alliance